Roche still keen on $44bn Genentech bid
Roche, the Swiss pharmaceutical company, insists its $43.7bn takeover of Genentech can still go ahead, despite the perilous state of Europe’s debt markets.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
